Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Rui Kang, Mengdi Song, Zhou Fang & Kehai Liu. (2023) Nano-composite hydrogels of Cu-Apa micelles for anti-vasculogenic mimicry. Journal of Drug Targeting 31:2, pages 166-178.
Read now
Read now
Hongchao Zhen, Guangxin Li, Pengfei Zhao, Ying Zhang, Jing Wang, Junxian Yu & Bangwei Cao. (2020) Raltitrexed Enhances the Antitumor Effect of Apatinib in Human Esophageal Squamous Carcinoma Cells via Akt and Erk Pathways. OncoTargets and Therapy 13, pages 12325-12339.
Read now
Read now
Guohui Liu, Yanbo Wang, Chunbo Wang, Yunlong He & Mingyan E. (2020) Clinical efficacy and safety of apatinib as maintenance treatment in patients with advanced esophageal squamous cell carcinoma. Expert Review of Clinical Pharmacology 13:12, pages 1423-1430.
Read now
Read now
Hiroshi Imazeki & Ken Kato. (2020) Development of chemotherapeutics for unresectable advanced esophageal cancer. Expert Review of Anticancer Therapy 20:12, pages 1083-1092.
Read now
Read now
Jing Li, Yongxu Jia, Yaping Gao, Zhiwei Chang, Huiqiong Han, Jie Yan & Yanru Qin. (2019) Clinical efficacy and survival analysis of apatinib combined with docetaxel in advanced esophageal cancer. OncoTargets and Therapy 12, pages 2577-2583.
Read now
Read now
Yitian Wang, Li Min, Yong Zhou, Fan Tang, Yi Luo, Wenli Zhang, Hong Duan & Chongqi Tu. (2019) The efficacy and safety of apatinib in metastatic alveolar soft part sarcoma: a case series of six patients in one institution. Cancer Management and Research 11, pages 3583-3591.
Read now
Read now
Yitian Wang, Li Min, Yong Zhou, Yi Luo, Hong Duan & Chongqi Tu. (2018) The efficacy and safety of apatinib in Ewing’s sarcoma: a retrospective analysis in one institution. Cancer Management and Research 10, pages 6835-6842.
Read now
Read now
Dantong Sun, Helei Hou, Chuantao Zhang & Xiaochun Zhang. (2018) The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis. OncoTargets and Therapy 11, pages 6539-6554.
Read now
Read now
Li-Jun Liang, Yi-Xuan Wen, You-You Xia, Lei Wang, Jia-Yan Fei & Xiao-Dong Jiang. (2018) Apatinib combined with docetaxel as a salvage treatment for metastatic esophageal squamous cancer: a case report. OncoTargets and Therapy 11, pages 5821-5826.
Read now
Read now
Deze Zhao, Helei Hou & Xiaochun Zhang. (2018) Progress in the treatment of solid tumors with apatinib: a systematic review. OncoTargets and Therapy 11, pages 4137-4147.
Read now
Read now
Articles from other publishers (23)
Miaomiao Cheng, Qi Xin, Saiyu Ma, Mengyue Ge, Feng Wang, Xiyun Yan & Bing Jiang. (2023) Advances in the Theranostics of Oesophageal Squamous Carcinoma. Advanced Therapeutics 6:7.
Crossref
Crossref
Zhihuang Hu, Si Sun, Xinmin Zhao, Hui Yu, Xianghua Wu, Jialei Wang, Jianhua Chang & Huijie Wang. (2022) Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study. The Oncologist 27:4, pages 253-e312.
Crossref
Crossref
Xiangrui Meng, Tao Wu, Yonggui Hong, Qingxia Fan, Zhonghai Ren, Yanzhen Guo, Xiuli Yang, Pei Shi, Jiamei Yang, Xianzhe Yin, Zhiquan Luo, Jin Xia, Yue Zhou, Mengli Xu, Enjie Liu, Guozhong Jiang, Shenglei Li, Feng Zhao, Chi Ma, Chuanxiang Ma, Zhiguo Hou, Jing Li, Junsheng Wang & Feng Wang. (2022) Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial. The Lancet Gastroenterology & Hepatology 7:3, pages 245-253.
Crossref
Crossref
Rixin Su, Jingya Zhu, Shusheng WuHuiqin Luo & Yifu He. (2022) Prognostic Significance of Platelet (PLT) and Platelet to Mean Platelet Volume (PLT/MPV) Ratio During Apatinib Second-Line or Late-Line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients. Technology in Cancer Research & Treatment 21, pages 153303382110729.
Crossref
Crossref
Yao Zhang, Yang Cai, Shi-Ru Zhang, Chong-Yong Li, Ling-Ling Jiang, Pin Wei & Ming-Fang He. (2021) Mechanism of hepatotoxicity of first-line tyrosine kinase inhibitors: Gefitinib and afatinib. Toxicology Letters 343, pages 1-10.
Crossref
Crossref
Dongmei Chi, Baoqing Chen, Suping Guo, Kunhao Bai, Huali Ma, Yonghong Hu, Qiaoqiao Li & Yujia Zhu. (2021) Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy. Aging 13:6, pages 8408-8420.
Crossref
Crossref
Bin Wei, Yuanyuan Wang, Jiawei Wang, Xiaomin Cai, Lingyan Xu, Jingjing Wu, Ying Wang, Wen Liu, Yanhong Gu, Wenjie Guo & Qiang Xu. (2020) Apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer via the Akt/β-catenin pathway. Cancer Cell International 20:1.
Crossref
Crossref
Bo Zhang, Ling Qi, Xi Wang, Jianping Xu, Yun Liu, Lan Mu, Xingyuan Wang, Lidan Bai & Jing Huang. (2020) Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma. Cancer Communications 40:12, pages 711-720.
Crossref
Crossref
Lei Wei, Bo Wang, Liwen Hu, Yang Xu, Zhongdong Li, Yi Shen & Hairong Huang. (2020) MEX3A is upregulated in esophageal squamous cell carcinoma (ESCC) and promotes development and progression of ESCC through targeting CDK6. Aging 12:21, pages 21091-21113.
Crossref
Crossref
Yan-Ming Yang, Pan Hong, Wen Wen Xu, Qing-Yu He & Bin Li. (2020) Advances in targeted therapy for esophageal cancer. Signal Transduction and Targeted Therapy 5:1.
Crossref
Crossref
Li Yanwei, He Feng, Peng Ren, Jie Yue, Wencheng Zhang, Peng Tang, Xiaobin Shang, Qingsong Pang, Dongying Liu, Chuangui Chen, Zhanyu Pan & Yu Zhen Tao. (2020) Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study. The Oncologist 25:10, pages e1464-e1472.
Crossref
Crossref
Xiangrong Zhao, Yuehong Kong & Liyuan Zhang. (2020) Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Negative Patient With Refractory Metastatic Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review. Frontiers in Oncology 10.
Crossref
Crossref
Wei Li, Chengguan Feng, Weihong Di, Shanwen Hong, Hui Chen, Mubashir Ejaz, Yang Yang & Tian-rui Xu. (2020) Clinical use of vascular endothelial growth factor receptor inhibitors for the treatment of renal cell carcinoma. European Journal of Medicinal Chemistry 200, pages 112482.
Crossref
Crossref
Dingyi Jiang, Yunyun Xu, Yunwang Chen, Jiahong Jiang, Mingxing Wang, Min Yang, Zheling Chen & Liu Yang. (2020) Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review. Frontiers in Pharmacology 11.
Crossref
Crossref
Jun-Hui Guo, Yuan-Yuan Wang, Jiang-Wei Zhang, Pei-Min Liu, Yan-Jun Hao & Hai-Rui Duan. (2020) Clinical effects of apatinib mesylate for treatment of multiple brain micrometastases: Two case reports. World Journal of Clinical Cases 8:7, pages 1326-1336.
Crossref
Crossref
Jian Zhao, Junmei Lei, Junyan Yu, Chengyan Zhang, Xuefeng Song, Ninggang Zhang, Yusheng Wang & Suxiang Zhang. (2019) Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma. Investigational New Drugs 38:2, pages 500-506.
Crossref
Crossref
Ken Kato. 2020. Esophageal Squamous Cell Carcinoma. Esophageal Squamous Cell Carcinoma
253
282
.
Ping Fang, Liqin Zhang, Xianru Zhang, Jiawen Yu, Jun Sun, Qi-an Jiang, Mingbao Zha, Anastasia P. Nesterova & Hongbao Cao. (2019) Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance —A Multicenter Randomized Trial. Scientific Reports 9:1.
Crossref
Crossref
Aiyi Li, Kong Wang, Aiguo Xu, Gang Wang, Yongchang Miao, Zhichao Sun & Jingyu Zhang. (2019) Apatinib as an optional treatment in metastatic colorectal cancer. Medicine 98:35, pages e16919.
Crossref
Crossref
Zhichao Tian, Zhiyuan Gu, Xin Wang, Zhiyong Liu, Weitao Yao, Jiaqiang Wang, Peng Zhang, Qiqing Cai & Hong Ge. (2019) Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy. Medicine 98:19, pages e15650.
Crossref
Crossref
Hui-Qin Luo, Yi-Fu He, Wen-Ju Chen, Ying Yan, Shu-Sheng Wu, Xiao-Xiu Hu, Li-Hong Ke, Jia-Yu Niu, Hui-Min Li & Hui-jun Xu. (2019) Effect of Apatinib on Serum CD4+CD25+ T cells, NK Cells, and T Cells Subgroup in Malignant Tumor. Technology in Cancer Research & Treatment 18, pages 153303381989366.
Crossref
Crossref
Jianxin Chen, Junhui Wang & Qian Miao. (2019) Careful dose modification of apatinib as third or further-line treatment in advanced gastric cancer patients with poor performance status. Medicine 98:45, pages e17890.
Crossref
Crossref
Lesley J. Scott. (2018) Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers. Drugs 78:7, pages 747-758.
Crossref
Crossref